Bioinductive Collagen Graft for Rotator Cuff Tears
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to determine if a new treatment using a collagen graft, known as the Regeneten Bioinductive Implant, can improve recovery for individuals with large rotator cuff tears in the shoulder. The trial compares two treatments: one group receives the standard surgical repair with tissue removal (debridement), while the other group receives the same surgery plus a collagen graft to bridge tendon gaps. Suitable participants have a large shoulder tear over 3 cm, confirmed by an MRI, and experience significant shoulder issues affecting daily activities. The trial seeks to identify which approach results in better shoulder function and fewer re-tears after one year. As an unphased trial, this study provides patients the chance to contribute to innovative research that could enhance future treatment options.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that this bioinductive collagen graft is safe for rotator cuff repair?
Research shows that using a bioinductive collagen graft, like the Regeneten implant, is generally safe for fixing rotator cuff tears. Studies have found that this treatment can help tendons heal better and become stronger. Many patients report feeling less pain and having improved shoulder movement after receiving the graft.
The Regeneten implant consists of purified collagen, a protein derived from cows. This collagen aids the damaged tendon by creating a supportive environment for new tissue growth. The implant is absorbable, naturally breaking down in the body over time.
Studies have not identified any major safety concerns with this collagen graft. Most patients tolerate it well, suggesting that the treatment is safe and promising for those with rotator cuff injuries.12345Why are researchers excited about this trial?
Unlike the standard rotator cuff repair, which typically involves just stitching up the tear, the Regeneten treatment incorporates a bioinductive collagen graft. This graft is delivered to the subacromial space and placed over the tendon, promoting natural tissue growth right where it's needed. Researchers are excited because this approach not only supports the repair but also potentially enhances healing by encouraging the body to rebuild stronger tendon tissue. This could mean more effective and quicker recoveries for patients compared to conventional repair methods.
What evidence suggests that this trial's treatments could be effective for rotator cuff tears?
Studies have shown that using a special collagen patch, such as the Regeneten, can enhance recovery for rotator cuff tears. In this trial, participants in the Graft-Augmented arm will receive this collagen patch along with the standard rotator cuff repair. Patients with these patches often experience less pain and improved shoulder movement after surgery. Research indicates that this treatment can also reduce the risk of recurrent tears. Some reports suggest that individuals with these patches heal better and have fewer repeat tears compared to those undergoing only traditional surgery, which participants in the Non-augmented arm will receive. Although more studies are needed to confirm these findings, early results appear promising for those with difficult-to-heal rotator cuff injuries.14567
Who Is on the Research Team?
Ivan Wong, MD
Principal Investigator
Orthopaedic Surgeon
Are You a Good Fit for This Trial?
Adults over 18 with MRI-confirmed large rotator cuff tears (>3cm) are eligible for this trial. It's not suitable for those with shoulder cancer, arthritis, certain types of tear and osteoarthritis, high WORC scores, uncontrolled diabetes (Hgb A1C >7%), infections, comprehension issues post-surgery, nonvascular surgical sites, poor nutrition (Alb <30 g/L), inability to consent, pregnancy or shoulder paralysis/contracture.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo either a regular rotator cuff repair with debridement or a graft-augmented repair with a bioinductive collagen implant
Early Recovery
Participants recover from surgery and initial outcomes such as pain and shoulder function are assessed
Follow-up
Participants are monitored for healing, re-tear rates, and overall shoulder function
What Are the Treatments Tested in This Trial?
Interventions
- Regeneten
Regeneten is already approved in United States, Canada for the following indications:
- Rotator cuff tears
- Partial-thickness rotator cuff tears
- Full-thickness rotator cuff tears
- Rotator cuff tears
- Partial-thickness rotator cuff tears
- Full-thickness rotator cuff tears
Find a Clinic Near You
Who Is Running the Clinical Trial?
Ivan Wong
Lead Sponsor
Smith & Nephew, Inc.
Industry Sponsor
Dr. Maria Berkman
Smith & Nephew, Inc.
Chief Medical Officer since 2023
MD from Harvard Medical School
Dr. Deepak Nath
Smith & Nephew, Inc.
Chief Executive Officer since 2022
PhD in Theoretical Mechanics, University of California, Berkeley